ADVM Adverum Biotechnologies
- 5.7500
- -0.4200-6.81%
Adverum Biotechnologies News
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
H.C. Wainwright Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $30
Buy Rating on Adverum Biotechnologies: Ixo-vec's Promising Potential in Transforming Wet AMD Treatment
Adverum Biotechnologies Analyst Ratings
RBC Capital Initiates Adverum Biotechnologies(ADVM.US) With Hold Rating, Announces Target Price $10
TD Cowen Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
A Quick Look at Today's Ratings for Adverum Biotechnologies(ADVM.US), With a Forecast Between $10 to $30
Buy Rating on Adverum Biotechnologies Driven by Ixo-vec's Promising Data and Potential Impact on AMD Treatment
Adverum Biotechnologies (ADVM) Gets a Buy From TD Cowen
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Chardan Capital Upgrades Adverum Biotechnologies(ADVM.US) to Buy Rating
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $20
Oppenheimer Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $28
Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $20
Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating
Analysis
Price Target
No Data
No Data